Medovex Corporation Expands Launch Plan With Latin American Management Hire

ATLANTA, GA--(Marketwired - Aug 29, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company has hired Mr. Juan Davila as Director Sales & Marketing for their DenerveX™ division of the business.

Mr. Davila, a Sales & Marketing leader with more than over 20 years of experience in the Latin-American Market, is recognized for his excellent record of business growth and market development of new products in the highly competitive medical devices industry in Latin America. Mr. Davila has a strong marketing and communication skills, in both Spanish and Portuguese.

Davila will be developing and implementing an overall corporate sales, marketing and strategy, directly engaging and managing all future Medovex Distributors throughout the Americas, and translating the company's business objectives into marketing strategies that drive future revenue. In addition, Mr. Davila will also provide services to help introduce the Medovex's DenerveX™ System to leading physicians and medical professionals in Latin America.

"Juan drives market awareness and qualified sales leads through a rare combination of medical technology savvy, customer, distributor focus and persuasive communication," said Manfred Sablowski, Medovex Senior Vice President Global Sales & Marketing. "His skill set spans all aspects of Sales & Marketing, and we are thrilled to be adding such a deep talent to the Medovex team."

Sablowski continues, "Juan Davila fits our mission to provide a world-wide distribution channel for our DenerveX System, while serving an important market segment in Latin America."

Prior to accepting this position, Davila established successful his own consulting firm with focus on the Latin American Healthcare Market and worked for Worldwide well known Medical Technology Companies like Valleylab (former Tyco/U.S Surgical/Pfizer) as General Manager Latin America which resulted in sales growth of 850% as well as Howmedica (former Pfizer).

The Company's patented DenerveX™ System is intended to treat Facet Joint Syndrome (FJS), a condition in which the joints in the back of the spine degenerate and subsequently cause pain. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to FJS pain.

The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX is not yet commercially available.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.